Learn
Retatrutide (LY3437943)
Research Compound Reference | Technical Peptide Library
Retatrutide is a synthetic, lipid-conjugated peptide consisting of 39 amino acid residues. Identified by CAS number 2381089-83-2 and research code LY3437943, it is classified as a unimolecular triple agonist of the GIP, GLP-1, and glucagon receptors.
Its molecular design combines a modified GIP-derived peptide backbone with nonstandard amino acid substitutions and a C20 fatty diacid conjugate. These structural features influence receptor recognition, resistance to enzymatic degradation, and molecular interactions with albumin.
Retatrutide is studied through chemical characterization, receptor-binding assays, cell-based signaling experiments, and peptide analytical methods.
This technical reference examines its molecular identity, structural modifications, receptor pharmacology, physicochemical behavior, analytical testing, and stability considerations.
Retatrutide Molecular Profile
| Property | Scientific information |
|---|---|
| Compound name | Retatrutide |
| Research identifier | LY3437943 |
| Alternative name | Triple G |
| CAS number | 2381089-83-2 |
| Molecular formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular weight | Approximately 4,731.34 g/mol |
| Amino acid count | 39 residues |
| Peptide classification | Synthetic lipidated polypeptide |
| Structural backbone | Modified GIP-derived sequence |
| Primary receptor targets | GIPR, GLP-1R, GCGR |
| Nonstandard amino acids | Aib at positions 2 and 20; α-methyl-L-leucine at position 13 |
| Lipid modification | C20 fatty diacid conjugation |
| Lipid attachment position | Lysine residue 17 |
| C-terminal structure | Serinamide |
| Primary research fields | Peptide chemistry, receptor pharmacology, analytical characterization |
| Regulatory status | Investigational; not FDA-approved |
The chemical formula and molecular weight describe the reference molecular structure. Salt forms, counterions, hydration, and other material-specific characteristics should be considered separately when interpreting analytical results.
Purity, physical form, and individual batch specifications are not universal molecular properties. They must be established through the Certificate of Analysis associated with the actual research material.
1. What Is Retatrutide?
Retatrutide, also known as LY3437943, is an engineered peptide developed from a glucose-dependent insulinotropic polypeptide (GIP) backbone.
It belongs to the family of multi-receptor peptide agonists.
An agonist is a molecule capable of interacting with a receptor and activating its signaling function.
Retatrutide is described as a triple agonist because its molecular structure supports activity at three different receptors:
- Glucose-dependent insulinotropic polypeptide receptor (GIPR)
- Glucagon-like peptide-1 receptor (GLP-1R)
- Glucagon receptor (GCGR)
These receptors belong to the class B family of G protein-coupled receptors.
Unlike a formulation containing three separate receptor agonists, Retatrutide consists of a single chemically engineered peptide with activity at all three receptor targets.
The molecule incorporates sequence modifications and lipid conjugation to alter its pharmacological and physicochemical characteristics.
Its design was described in the original 2022 research published in Cell Metabolism.
Why Is Retatrutide Classified as a Modified Peptide?
Natural peptide hormones consist of amino acid chains that can interact with specific receptors.
Researchers can modify those chains by replacing amino acids, introducing nonstandard residues, or attaching additional chemical groups.
Retatrutide contains all three types of structural engineering.
Its modifications distinguish it from the natural GIP sequence while allowing interactions with related receptor families.
The result is a chemically defined peptide that can be studied using receptor-based laboratory assays and analytical chemistry techniques.
2. Retatrutide Molecular Architecture
Retatrutide contains a 39-residue peptide backbone.
The sequence originates from the GIP peptide family but includes modifications selected to change receptor activity and molecular stability.
Three major structural features are particularly important:
- Nonstandard amino acid substitutions.
- A fatty diacid conjugate attached through a linker.
- A modified C-terminal structure.
These features influence the chemical and physical properties of the complete molecule.
Alpha-Aminoisobutyric Acid (Aib) Substitutions
Retatrutide contains alpha-aminoisobutyric acid, abbreviated Aib, at positions 2 and 20.
Aib is a non-proteinogenic amino acid.
Unlike standard amino acids used during natural protein synthesis, Aib introduces distinct structural characteristics into a peptide backbone.
At position 2, Aib contributes to resistance against cleavage by dipeptidyl peptidase-4 (DPP-4).
DPP-4 is an enzyme capable of cleaving several naturally occurring peptide hormones.
The Aib residue at position 20 contributes to the designed receptor activity and physicochemical properties of Retatrutide.
Alpha-Methyl-L-Leucine at Position 13
Retatrutide contains alpha-methyl-L-leucine at position 13.
This residue differs from conventional leucine because of the additional methyl substitution at the alpha carbon.
Alpha-methylation can restrict conformational flexibility and influence receptor recognition.
In the original molecular development research, this modification was associated with optimization of glucagon and GIP receptor activity.
C20 Fatty Diacid Conjugation
Another defining structural feature is the attachment of a C20 fatty diacid group.
The lipid-containing side chain is connected to lysine at position 17 through a chemical linker.
This modification introduces a lipophilic region into an otherwise highly polar peptide molecule.
Fatty-acid conjugation can alter molecular interactions with proteins, solvents, and other components in an experimental system.
Why Does the Fatty Diacid Matter?
The fatty diacid conjugate promotes reversible interactions with albumin.
Albumin is a protein capable of binding various endogenous and synthetic molecules.
In peptide engineering, albumin-binding modifications are used to alter pharmacokinetic behavior.
The presence of the lipid side chain also introduces analytical and formulation considerations, including amphiphilic behavior and possible interactions with laboratory surfaces.
C-Terminal Serinamide
The Retatrutide peptide backbone terminates in a serinamide group.
C-terminal amidation changes the terminal functional group relative to a peptide ending in a free carboxylic acid.
This structural detail is part of the defined molecular identity and should be accounted for during theoretical mass calculations and sequence verification.
3. Retatrutide Receptor Pharmacology
Retatrutide has been characterized in laboratory assays involving GIP, GLP-1, and glucagon receptors.
These receptors are membrane-associated proteins that transmit extracellular molecular signals into cells.
All three belong to the class B G protein-coupled receptor family.
GIP Receptor (GIPR)
GIPR is the receptor for glucose-dependent insulinotropic polypeptide.
Laboratory studies investigate how different peptide ligands interact with GIPR and activate intracellular pathways.
Retatrutide demonstrates functional agonist activity at this receptor.
GLP-1 Receptor (GLP-1R)
GLP-1R is the receptor for glucagon-like peptide-1.
It is commonly used in experiments examining peptide-receptor binding, receptor activation, and intracellular signaling.
Retatrutide’s modified molecular structure enables it to interact with GLP-1R despite being developed from a GIP-derived backbone.
Glucagon Receptor (GCGR)
GCGR is the receptor for glucagon.
It belongs to the same broad GPCR family as GIPR and GLP-1R.
Retatrutide also activates GCGR, completing its triple-agonist receptor profile.
Receptor Signaling and cAMP
A major method of examining these receptors involves measuring cyclic adenosine monophosphate, or cAMP.
Receptor activation can stimulate Gs-associated signaling, leading to increased adenylyl cyclase activity and intracellular cAMP production.
In laboratory systems, cAMP measurements can provide information about a compound’s functional activity at a receptor.
The original Retatrutide discovery study used receptor-expressing cell lines and cAMP assays to characterize activity across all three receptor targets.
What Is EC50?
EC50 is the concentration of a compound that produces 50% of its maximal observed effect under a defined assay.
It is commonly used in receptor pharmacology.
A lower EC50 can indicate greater apparent potency under otherwise comparable conditions.
However, EC50 values are dependent on assay design, receptor expression, reference ligands, and other experimental factors.
For this reason, receptor potency values should be compared using appropriately matched experimental conditions.
4. Physicochemical Properties of Retatrutide
Retatrutide combines a polar peptide backbone with a lipid-containing side chain.
This combination gives the molecule amphiphilic characteristics.
An amphiphilic molecule contains regions with different affinities for aqueous and nonpolar environments.
Amphiphilic Behavior
The peptide backbone contains numerous amide groups and polar side chains.
These groups can interact with water and other polar molecules.
The fatty diacid modification contributes a hydrophobic region.
The balance between these properties may influence solubility, aggregation, protein interactions, and surface adsorption.
Solubility Considerations
The solubility of a lipid-modified peptide cannot be determined from molecular weight alone.
Important variables may include:
- Peptide concentration
- Solution pH
- Ionic strength
- Buffer composition
- Temperature
- Counterion composition
- Presence of other chemical substances
Measured solubility should be reported under clearly defined laboratory conditions.
A visually clear solution does not by itself establish chemical stability, complete dissolution, or the absence of molecular aggregates.
Surface Adsorption
Peptides may interact with laboratory materials, including glass, plastic, and other surfaces.
Adsorption can affect the amount of peptide remaining in a sample.
For lipidated peptides, this may depend on the balance between their polar and hydrophobic regions.
Analytical recovery studies can help identify whether adsorption affects experimental measurements.
Aggregation
Peptide aggregation occurs when molecules associate into larger assemblies.
Aggregation behavior depends on molecular structure and environmental conditions.
Researchers evaluating a modified peptide may examine whether changes in solution conditions influence molecular association.
Aggregation cannot be ruled out solely through visual inspection.
5. Analytical Characterization of Retatrutide
Analytical characterization is used to establish the identity, composition, and selected quality attributes of a research compound.
Retatrutide’s molecular structure requires methods capable of evaluating both its peptide backbone and lipid-containing modification.
Several complementary analytical techniques may be appropriate.
High-Performance Liquid Chromatography (HPLC)
HPLC separates components according to their interaction with a chromatographic system.
Reversed-phase HPLC is commonly used to characterize synthetic peptides.
It can help separate a target peptide from certain related impurities and degradation compounds.
The result is often displayed as a chromatogram containing one or more peaks.
A chromatographic purity value is calculated according to the method used.
However, HPLC peak-area purity is not necessarily equivalent to total mass purity or absolute peptide content.
Mass Spectrometry (MS)
Mass spectrometry measures the mass-to-charge ratios of ionized molecules.
It can provide evidence that the analyzed material contains a molecular species with a mass consistent with the expected Retatrutide structure.
For large peptides, electrospray ionization may produce multiple charge states.
Analytical software can use these signals to calculate a deconvoluted molecular mass.
The expected molecular structure should be used when interpreting the result.
Liquid Chromatography-Mass Spectrometry (LC-MS)
LC-MS combines chromatographic separation with mass analysis.
This approach can help researchers investigate the molecular identities of different chromatographic components.
It may also support characterization of certain peptide-related impurities or degradation compounds.
Peptide Sequence Verification
Molecular weight alone cannot uniquely establish amino acid sequence.
Two peptides may have similar or identical masses while differing in residue arrangement or stereochemistry.
More detailed structural characterization may require methods designed to examine sequence and modification sites.
The appropriate analytical approach depends on the specific identity question being investigated.
Analytical Methods Overview
| Method | Main information provided |
|---|---|
| RP-HPLC | Chromatographic profile and certain impurities |
| Mass spectrometry | Molecular mass-related evidence |
| LC-MS | Mass information associated with separated components |
| LC-MS/MS | Additional structural or sequence-related evidence |
| Peptide content assay | Amount of peptide under a defined method |
| Water content analysis | Moisture-related information |
| Stability-indicating analysis | Changes during controlled storage studies |
No single analytical technique establishes every quality attribute.
Complementary methods provide a stronger basis for characterization.
6. Understanding a Retatrutide Certificate of Analysis
A Certificate of Analysis, or COA, reports results from specified tests performed on an identified sample or batch.
For a modified peptide such as Retatrutide, a useful COA should clearly connect analytical results to the actual material being assessed.
Important COA Information
| COA field | What it establishes |
|---|---|
| Compound name | Reported identity of the material |
| Batch or lot number | Which material was analyzed |
| CAS number | Reference chemical identifier |
| Molecular formula | Theoretical elemental composition |
| Expected molecular weight | Reference mass for comparison |
| HPLC chromatogram | Chromatographic characteristics |
| HPLC purity | Reported result under the specified method |
| Mass spectrometry results | Evidence relating to molecular mass |
| Peptide content | Measured content, if tested |
| Analytical date | When measurements were performed |
| Laboratory identification | Organization responsible for testing |
What Does 99% HPLC Purity Mean?
If a COA reports 99% HPLC purity, the figure usually refers to a calculation based on chromatographic peak areas.
The value must be interpreted according to the method and detection conditions.
It does not necessarily mean that 99% of the material’s total mass consists of the intended peptide.
Water, counterions, residual solvents, or substances not detected by the method may affect total composition.
Does Mass Spectrometry Confirm Purity?
Mass spectrometry supports molecular identification but does not automatically establish quantitative purity.
A mass consistent with Retatrutide is useful evidence.
However, additional testing may be necessary to identify impurities, sequence variants, or material-specific characteristics.
Why Is Lot-Specific Documentation Important?
Synthetic peptide batches may differ in impurity profiles, residual substances, and other analytical characteristics.
Therefore, results from one batch cannot automatically establish the properties of another batch.
A lot-matched COA is more informative than a generic analytical report.
7. Retatrutide Stability and Degradation
The stability of a peptide refers to its ability to retain defined chemical and physical characteristics under specified conditions.
Retatrutide contains multiple amide bonds, chemically modified residues, and a lipid-containing side chain.
These features should be considered when designing or interpreting analytical stability studies.
Factors That Can Influence Stability
Several variables may influence the stability of a peptide research material:
Temperature: Changes in temperature can alter chemical reaction rates and physical behavior.
Moisture: Water exposure may influence some degradation processes, particularly in solid materials.
pH: Changes in acidity or alkalinity can affect ionization and chemical reactivity.
Oxidation: Some molecular groups are susceptible to oxidative reactions.
Light: Light exposure may promote chemical changes in susceptible compounds.
Solution composition: Buffers, salts, and other components can influence stability.
Lyophilized Material vs Solution
Lyophilization removes water through a freeze-drying process.
This can improve the storage properties of certain peptide formulations.
However, a lyophilized appearance does not guarantee a particular shelf life.
The stability of a dried peptide depends on factors including residual moisture, packaging, and formulation composition.
In solution, additional processes such as hydrolysis, adsorption, and molecular association may become relevant.
How Is Retatrutide Stability Evaluated?
Researchers may examine samples over time using stability-indicating analytical methods.
A stability study may track changes in chromatographic profiles, molecular mass, peptide content, and other defined quality attributes.
Results should document the tested material, environmental conditions, observation period, and analytical methods.
Storage temperatures and expiry periods should be based on actual stability evidence rather than copied from unrelated peptide compounds.
8. Retatrutide Compared With Other Modified Peptides
Retatrutide belongs to a broader group of engineered peptide receptor agonists.
Related compounds include Semaglutide and Tirzepatide.
All three contain structural modifications that distinguish them from their corresponding natural hormone sequences.
However, their molecular designs and receptor profiles differ.
Retatrutide vs Semaglutide
Semaglutide is a modified GLP-1 analog.
Its primary receptor target is GLP-1R.
Retatrutide uses a GIP-derived backbone and is designed to activate GIPR, GLP-1R, and GCGR.
Both molecules incorporate fatty-acid-based modifications, but their sequences and conjugation architectures are different.
Retatrutide vs Tirzepatide
Tirzepatide is a 39-residue synthetic peptide with activity at GIPR and GLP-1R.
Retatrutide also contains 39 residues but incorporates a different molecular design to achieve activity at three receptors.
Both compounds have lipid modifications associated with albumin interactions.
They should not be treated as chemically identical or interchangeable.
Molecular Comparison
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Amino acid residues | 39 | 39 | 31 |
| Structural family | GIP-derived | GIP-derived | GLP-1-derived |
| GIPR activity | Yes | Yes | No |
| GLP-1R activity | Yes | Yes | Yes |
| GCGR activity | Yes | No | No |
| Fatty-acid modification | Yes | Yes | Yes |
| Single defined peptide molecule | Yes | Yes | Yes |
The comparison describes molecular design and receptor pharmacology, not clinical performance.
9. Common Technical Questions About Retatrutide
What is Retatrutide?
Retatrutide is a synthetic 39-amino-acid lipid-conjugated peptide with agonist activity at GIP, GLP-1, and glucagon receptors.
What is the research identifier of Retatrutide?
Its research identifier is LY3437943.
What is Retatrutide’s CAS number?
The CAS Registry Number is 2381089-83-2.
What is the molecular formula of Retatrutide?
The commonly reported reference formula is C₂₂₁H₃₄₂N₄₆O₆₈.
What is Retatrutide’s molecular weight?
The reference molecular weight is approximately 4,731.34 g/mol.
How many amino acids are in Retatrutide?
The peptide contains 39 amino acid residues.
Is Retatrutide a linear or cyclic peptide?
Retatrutide contains a single, noncyclic peptide backbone with a conjugated lipid-containing side chain. It is not classified as a cyclic peptide.
What are the key structural modifications?
The molecule contains Aib substitutions at positions 2 and 20, alpha-methyl-L-leucine at position 13, and a C20 fatty diacid conjugated through lysine-17.
Why does Retatrutide contain a fatty diacid?
The modification supports albumin binding and contributes to the molecular properties of the engineered peptide.
What receptor targets are associated with Retatrutide?
GIPR, GLP-1R, and GCGR.
What does triple agonist mean?
It describes one molecule capable of activating three different receptor targets.
How is Retatrutide identified analytically?
Mass spectrometry, chromatographic methods, and other structural characterization techniques may be used to assess molecular identity.
What does HPLC measure?
HPLC separates components and can provide chromatographic purity information under defined analytical conditions.
Does 99% HPLC purity establish complete chemical purity?
No. HPLC peak-area purity does not necessarily describe total chemical content or exclude substances that are not detected by the method.
What does a Retatrutide COA show?
A COA reports specified analytical results for an identified batch or sample.
Why is Retatrutide called amphiphilic?
Its peptide backbone contains polar chemical groups, while its fatty diacid modification contributes a lipophilic region.
Can Retatrutide undergo degradation?
Yes. Like other complex peptides, it can undergo chemical or physical changes depending on environmental conditions.
Does Retatrutide have a universal laboratory shelf life?
No. A supported shelf-life claim requires stability data for the exact material and formulation.
Is Retatrutide the same molecule as Tirzepatide?
No. They have different sequences, structural modifications, and receptor activity profiles.
Is Retatrutide FDA-approved?
No. Retatrutide remains investigational and has not received FDA approval.
10. Scientific References and Chemical Databases
Original Molecular Development Research
Coskun T. et al. (2022)
LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist: From Discovery to Clinical Proof of Concept.
Journal: Cell Metabolism
Research relevance: Molecular design, nonstandard amino acid substitutions, fatty diacid conjugation, and receptor characterization.
https://doi.org/10.1016/j.cmet.2022.07.013
Cell-Based Receptor Research
Differentiation of Human Subcutaneous Adipocytes and Measurement of Lipolytic Function Induced by GIP or LY3437943 (2023)
Journal: STAR Protocols
Research relevance: Experimental cellular models and analytical approaches used in receptor-related research.
https://doi.org/10.1016/j.xpro.2023.102304
Chemical Structure Database
KEGG Drug: Retatrutide (D12430)
Reference information: Molecular formula, molecular weight, structural representation, peptide sequence, and receptor classification.
PubChem Chemical Identifier
PubChem: Retatrutide
Reference information: CAS number, chemical identifiers, synonyms, and linked compound records.
Conclusion
Retatrutide is a structurally engineered 39-residue peptide characterized by a modified GIP-derived backbone, nonstandard amino acid substitutions, and a C20 fatty diacid conjugate.
Its molecular architecture supports agonist activity at three related G protein-coupled receptors: GIPR, GLP-1R, and GCGR.
From an analytical perspective, the compound presents several important areas of investigation, including receptor activity, molecular identity, chromatographic separation, mass spectrometric characterization, amphiphilic behavior, and stability.
Accurate scientific documentation requires clear identification of the reference structure and careful interpretation of material-specific analytical results.
For laboratory research, chemical identity, theoretical molecular properties, chromatographic purity, measured peptide content, and stability are separate attributes that must not be confused.
Research disclaimer: This page is intended for scientific education and technical reference only. Retatrutide is investigational and is not FDA-approved. It does not provide instructions for personal use, dosing, administration, or medical treatment. Analytical information does not establish that any commercial research material is suitable for human or veterinary use.
